Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Guidance & outlook
Kiniksa Pharmaceuticals International (KNSA) guidance and outlook
Kiniksa Pharmaceuticals International (KNSA) raised its guidance on Oct 27, 2026: Revenue (segment) $1.0B–$1.1B for FY2026. Kiniksa Pharmaceuticals International's 10-Q filed Jul 28, 2026 makes 19 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.0B–$1.1B | raised |
From the earnings release filed Oct 27, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Jul 28, 2026
- In addition, we announced that we expect to begin commercializing KPL-387 in 2028 or 2029.
- We are currently conducting preclinical activities with respect to this asset, and expect to initiate a Phase 1 first-in-human clinical trial by the end of 2026.
- In February 2025, we announced our plans to discontinue development of abiprubart in Sjogren's Disease and to explore strategic alternatives for the asset.
- ARCALYST is currently only approved for sale in the United States, and, therefore, we expect to derive substantially all of our product revenue from the United States for the foreseeable future.
- These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances.
- In addition, we will be eligible to receive additional contingent sales-based milestones payments related to ARCALYST.
- Royalties will be payable on a country-by-country or region-by-region basis until the later of (i) 12 years after the first commercial sale of ARCALYST in such country or region in the Huadong Territory, (ii) the date of expiration of the last valid patent claim of our patent rights or any joint collaboration patent rights that covers ARCALYST in such country or region in the Huadong Territory, and (iii) the…
- Under the Genentech License Agreement, we will be eligible to receive up to a total of approximately $600.0 million in contingent payments, including specified development, regulatory and sales-based milestones, of which approximately $570.0 million remains as of June 30, 2026.
- We will also be eligible to receive tiered percentage royalties on a Genentech Licensed Product-by-Genentech Licensed Product basis ranging from low-double digits to mid-teens on annual net sales of each Genentech Licensed Product, subject to certain customary reductions, with an aggregate minimum floor, before fulfilling our upstream financial obligations.
- As a result, we expect that our research and development expenses will be substantial over the next several years as we conduct our ongoing and/or planned clinical trials for our product candidates, as well as conduct other preclinical and clinical development, and make regulatory filings for our product candidates.
- At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of our current or future product candidates or when, if ever, we will realize revenue from the sale of our current or future product candidates.
- We expect that our selling, general and administrative expenses will continue to increase in the future as we continue to expand our infrastructure related to the commercialization of ARCALYST and our other product candidates, if approved.
Kiniksa Pharmaceuticals International's latest quarter
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Kiniksa Pharmaceuticals International raise or lower its guidance?
Kiniksa Pharmaceuticals International (KNSA) raised its guidance on Oct 27, 2026: Revenue (segment) $1.0B–$1.1B for FY2026.
What does Kiniksa Pharmaceuticals International expect?
In addition, we announced that we expect to begin commercializing KPL-387 in 2028 or 2029. We are currently conducting preclinical activities with respect to this asset, and expect to initiate a Phase 1 first-in-human clinical trial by the end of 2026. In February 2025, we announced our plans to discontinue development of abiprubart in Sjogren's Disease and to explore strategic alternatives for the asset.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.